Outcomes Associated With Type of Milk Supplementation Among Late Preterm Infants.
Rebecca Mannel, Jennifer D Peck
https://pubmed.ncbi.nlm.nih.gov/29287170/Actively Recruiting
Led by AdventHealth · Updated on 2026-09-11
17
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research investigates very preterm infants born between 29.0 and 32.6 weeks of gestational age receiving donor breast milk DBM. The study evaluates whether starting iron supplementation earlier, when infants reach 80 mlkgday of enteral feeds, increases serum ferritin and hematocrit levels at 14 and 28 days of life compared to the current practice of starting at full feeds 140 to 160 mlkgday. The rationale is based on evidence that DBM has lower iron content due to pasteurization and that iron levels may impact neurodevelopment in preterm infants. Participants will receive oral ferrous sulfate supplementation at 2-4 mgkgday starting approximately 4-6 days after birth when they reach the feeding volume target. Blood samples will be taken at day 14 4 days and day 28 4 days or prior to discharge, whichever is earlier, to measure serum ferritin and hematocrit levels. These blood draws coincide with routine clinical blood collections to minimize discomfort. Iron supplementation is given earlier than the usual protocol that initiates supplementation around day 14. During the study, infants will be monitored in the neonatal intensive care unit with regular assessments of blood iron markers. Researchers will track serum ferritin and hematocrit levels at the specified time points to determine the effect of earlier iron supplementation. The total participation period spans from early feeding stages until day 28 or hospital discharge, with safety and growth monitored as part of routine care. The trial is sponsored by AdventHealth and aims to optimize iron supplementation timing to potentially improve neurodevelopmental outcomes.
CONDITIONS
Donor Breast Milk 2
A
Anoop Pulickal, MD, PhD
D
Deborah Ruth, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AdventHealth
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Early Oral Iron (Trial) | Routine Iron Supplementation (Guideline) |
|---|---|---|
| What it is | Early oral ferrous sulfate is given as a dietary supplement to very preterm infants receiving donor breast milk, starting within the first 5–14 days of life. | Routine enteral iron supplementation is recommended for very preterm infants fed donor breast milk or formula to meet iron needs and prevent anemia, typically initiated as infants approach full enteral feeds. |
| Role in trial | Serves as the primary intervention under investigation to support iron status and reduce anemia risk in very preterm infants fed DBM. | Serves as the standard nutritional care component for iron status maintenance in very preterm infants in the NICU. |
| Primary use | To maintain adequate iron status and prevent iron deficiency anemia in infants primarily fed donor breast milk. | To support normal hematologic development and protect against anemia in very preterm infants, including those fed DBM or formula. |
| How it is given or performed | Ferrous sulfate is administered orally to eligible infants, beginning within days 5–14 of life, as a supplement alongside DBM feedings. | Iron is typically given enterally as a daily supplement once infants tolerate full enteral feeds. Dose and start timing may vary by guideline and clinical condition. |
| Evidence status | Efficacy and safety are being actively studied; published evidence suggests early iron supplementation positively affects neurodevelopment and iron status. | Routine iron supplementation is strongly supported by guideline consensus and published reviews as effective for preventing iron deficiency anemia in very preterm infants. |
| Important limitations | As a single-group interventional study, direct comparison with alternative supplementation strategies or feeding regimens is not provided. Long-term safety in DBM-fed infants remains under investigation. | While routine iron supplementation is widely recommended, precise protocols may vary, and published evidence shows heterogeneity in dosing and timing. Donor milk is generally less supportive of growth and iron status than maternal milk. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days or until hospital discharge
Participants receive early iron supplementation starting when feeding volume reaches 80 ml/kg/day. Blood samples are collected at 14 and 28 days of life or before discharge to monitor iron and blood levels.
Routine clinical blood draws during NICU stay
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Rebecca Mannel, Jennifer D Peck
https://pubmed.ncbi.nlm.nih.gov/29287170/Anna-Lena Hård, Anders K Nilsson, Anna-My Lund...
https://pubmed.ncbi.nlm.nih.gov/30565323/Sertac Arslanoglu, Ekhard E Ziegler, Guido E Moro...
https://pubmed.ncbi.nlm.nih.gov/20443660/Section on Breastfeeding
https://pubmed.ncbi.nlm.nih.gov/22371471/Kendell R German, Phuong T Vu, Bryan A Comstock...
https://pubmed.ncbi.nlm.nih.gov/34324880/N Mohd-Taufek, D Cartwright, M Davies...
https://pubmed.ncbi.nlm.nih.gov/27253894/Ashish Kc, Nisha Rana, Mats Målqvist...
https://pubmed.ncbi.nlm.nih.gov/28114607/Maria Quigley, Nicholas D Embleton, William McGuire
https://pubmed.ncbi.nlm.nih.gov/31322731/Elisabeth Stoltz Sjöström, Inger Ohlund, Andreas Tornevi...
https://pubmed.ncbi.nlm.nih.gov/25117506/Judith S Mercer, Debra A Erickson-Owens, Sean C L Deoni...
https://pubmed.ncbi.nlm.nih.gov/30473033/AdventHealth
Lead Sponsor